Research programme: subcutaneous formulation of monoclonal antibodies - Comera Life Sciences
Latest Information Update: 05 Apr 2023
At a glance
- Originator ReForm Biologics
- Developer Comera Life Sciences
- Class Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer; Cardiovascular disorders; Crohn's disease; Inflammation
Most Recent Events
- 05 Apr 2023 Comera Life Sciences receives Notices of Allowance in the US and Japan covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore™ platform
- 03 Apr 2023 Comera Life Sciences has patent protection in South Korea covering expansion of claims and exclusive rights pertaining to certain excipients in its proprietary SQore™ platform
- 31 Jan 2023 Early research in Cardiovascular disorders in USA (SC) (Comera Life Sciences pipeline, January 2023)